Cargando…

Endocrine therapies in breast cancer /

Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of t...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Buzdar, Aman U.
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Oxford ; New York : Oxford University Press, 2007.
Colección:Oxford oncology library.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 a 4500
001 EBOOKCENTRAL_ocn801405943
003 OCoLC
005 20240329122006.0
006 m o d
007 cr cnu---unuuu
008 120723s2007 enka ob 001 0 eng d
010 |z  2007038907 
040 |a N$T  |b eng  |e pn  |c N$T  |d E7B  |d OCLCQ  |d OCLCF  |d OCLCQ  |d NLGGC  |d OCLCO  |d YDXCP  |d OCLCQ  |d EBLCP  |d IDEBK  |d OCLCO  |d OCLCQ  |d AZK  |d OCLCO  |d LOA  |d STBDS  |d OCLCA  |d COCUF  |d TOA  |d OCLCO  |d AGLDB  |d OCLCO  |d MOR  |d CCO  |d PIFAG  |d ZCU  |d OCLCO  |d OCLCQ  |d MERUC  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCA  |d U3W  |d OCLCO  |d STF  |d OCLCO  |d WRM  |d VNS  |d OCLCO  |d VTS  |d NRAMU  |d ICG  |d VT2  |d AU@  |d OCLCO  |d OCLCQ  |d WYU  |d OCLCA  |d REC  |d OCLCO  |d DKC  |d OCLCQ  |d UX1  |d OCLCQ  |d OCLCA  |d UKCRE  |d UKAHL  |d AJS  |d OCLCQ  |d OCLCO  |d OCLCQ  |d QGK  |d OCLCO  |d OCLCL 
019 |a 801363649  |a 961618370  |a 962602314  |a 966212272  |a 988501072  |a 992094670  |a 1037791981  |a 1038614370  |a 1045514218  |a 1055366187  |a 1066545960  |a 1081286810  |a 1153554442  |a 1259216388 
020 |a 9780191575174  |q (electronic bk.) 
020 |a 0191575178  |q (electronic bk.) 
020 |z 9780199218141 
020 |z 0199218145 
020 |a 0191739871 
020 |a 9780191739873 
020 |a 0199606994 
020 |a 9780199606993 
020 |a 1283580756 
020 |a 9781283580755 
020 |a 9786613893208 
020 |a 661389320X 
029 1 |a AU@  |b 000051581297 
029 1 |a DEBBG  |b BV040834182 
029 1 |a DEBBG  |b BV043167333 
029 1 |a DEBBG  |b BV044167212 
029 1 |a DEBSZ  |b 421394935 
029 1 |a NZ1  |b 15338587 
035 |a (OCoLC)801405943  |z (OCoLC)801363649  |z (OCoLC)961618370  |z (OCoLC)962602314  |z (OCoLC)966212272  |z (OCoLC)988501072  |z (OCoLC)992094670  |z (OCoLC)1037791981  |z (OCoLC)1038614370  |z (OCoLC)1045514218  |z (OCoLC)1055366187  |z (OCoLC)1066545960  |z (OCoLC)1081286810  |z (OCoLC)1153554442  |z (OCoLC)1259216388 
050 4 |a RC280.B8  |b E523 2007eb 
060 4 |a WP 870  |b E56 2007 
072 7 |a HEA  |x 039030  |2 bisacsh 
072 7 |a MED  |x 062000  |2 bisacsh 
082 0 4 |a 616.99/449071  |2 22 
049 |a UAMI 
245 0 0 |a Endocrine therapies in breast cancer /  |c edited by Aman U. Buzdar. 
260 |a Oxford ;  |a New York :  |b Oxford University Press,  |c 2007. 
300 |a 1 online resource (viii, 120 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Oxford oncology library 
504 |a Includes bibliographical references and index. 
505 0 |a Selection of patients for endocrine therapies / W. Fraser Symmans and Lajos Pusztai -- Ovarian ablation / Kellie l. Jones -- Antioestrogens / John F. Forbes -- Aromatase inhibitors in early and advanced disease / Laura Boehnke Michaud -- Fulvestrant in metastatic disease / Amit Agrawal, J.F.R. Robertson, and K.L. Cheung -- Progestins and androgens / Janet l. Espirito -- Combined endocrine and chemotherapy in breast cancer / Ishmael Jaiyesimi [and others] -- Hormone replacement therapy in patients with a prior history of breast cancer / Gilbert G. Fareau and Rena Vassilopoulou-Sellin -- Chemoprevention / Saheenah Dawood and Jack Cuzick. 
588 0 |a Print version record. 
520 |a Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging. 
546 |a English. 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
590 |a eBooks on EBSCOhost  |b EBSCO eBook Subscription Academic Collection - Worldwide 
650 0 |a Breast  |x Cancer  |x Hormone therapy. 
650 0 |a Breast  |x Cancer  |x Endocrine aspects. 
650 1 2 |a Breast Neoplasms  |x drug therapy 
650 2 2 |a Antineoplastic Agents, Hormonal  |x therapeutic use 
650 6 |a Sein  |x Cancer  |x Hormonothérapie. 
650 6 |a Sein  |x Cancer  |x Aspect endocrinien. 
650 7 |a HEALTH & FITNESS  |x Diseases  |x Cancer.  |2 bisacsh 
650 7 |a MEDICAL  |x Oncology.  |2 bisacsh 
650 7 |a Breast  |x Cancer  |x Endocrine aspects  |2 fast 
650 7 |a Breast  |x Cancer  |x Hormone therapy  |2 fast 
700 1 |a Buzdar, Aman U. 
758 |i has work:  |a Endocrine therapies in breast cancer (Text)  |1 https://id.oclc.org/worldcat/entity/E39PCY97mpDWDjvdr8DyBgp8rV  |4 https://id.oclc.org/worldcat/ontology/hasWork 
776 0 8 |i Print version:  |t Endocrine therapies in breast cancer.  |d Oxford ; New York : Oxford University Press, 2007  |z 9780199218141  |w (DLC) 2007038907  |w (OCoLC)74966478 
830 0 |a Oxford oncology library. 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=975599  |z Texto completo 
938 |a Askews and Holts Library Services  |b ASKH  |n AH37530475 
938 |a EBL - Ebook Library  |b EBLB  |n EBL975599 
938 |a ebrary  |b EBRY  |n ebr10581391 
938 |a EBSCOhost  |b EBSC  |n 467600 
938 |a ProQuest MyiLibrary Digital eBook Collection  |b IDEB  |n 389320 
938 |a Oxford University Press USA  |b OUPR  |n EDZ0000091504 
938 |a YBP Library Services  |b YANK  |n 9316034 
938 |a YBP Library Services  |b YANK  |n 12890069 
994 |a 92  |b IZTAP